Navigation Links
Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference

KING OF PRUSSIA, Pa., Jan. 6 /PRNewswire/ -- Prism Pharmaceuticals, Inc. announced today that Dr. Warren D. Cooper, President and Chief Executive Officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 7:30 a.m. (Pacific Time) or 10:30 a.m. (Eastern Time). The conference will be held at the Westin St. Francis Hotel in San Francisco, California.

Dr. Cooper will present corporate strategy and highlight the recent FDA approval of the Company's new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV.

The presentation will be webcast live by visiting the Company's website at An archive of the presentation also will be available on the Company's website following the conference.

About Prism Pharmaceuticals

Prism Pharmaceuticals, based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. The product portfolio strategy is focused on recognizing unfulfilled opportunities in existing compounds that address current unmet medical needs with a specific focus on medication safety in the hospital environment.

For further information, visit

SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
2. Prism glasses expand the view for patients with hemianopia
3. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
4. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
5. AUDIO from Medialink and Solvay Pharmaceuticals: New Initiative Urges Women to Address Mens Health this New Year
6. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
7. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
8. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
9. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
10. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
11. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
Post Your Comments:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: